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Abstract
Febrile neutropenia (FN) is a serious complication of chemotherapy, which can cause significant morbidity and mortality, 
result in dose delays and reductions and, ultimately, reduce cancer survival. Over the past decade, the availability of bio-
similar filgrastim (short-acting granulocyte colony-stimulating factor [G-CSF]) has transformed patient access, with clear 
evidence of clinical benefit at preventing FN at reduced costs. In 2019, seven biosimilar pegfilgrastims (long-acting G-CSFs) 
were licensed, creating optimal market conditions and choice for prescribers. FN affects up to 117 per 1000 cancer patients, 
with mortality rates in the range of 2–21%. By reducing FN incidence and improving chemotherapy relative dose intensity 
(RDI), G-CSF has been associated with a 3.2% absolute survival benefit. Guidelines recommend primary prophylaxis and 
that filgrastim be administered for 10–14 days, while pegfilgrastim is administered once per cycle. When taken according 
to the guidelines, pegfilgrastim and filgrastim are equally effective. However, in routine clinical practice, filgrastim is often 
under-dosed (< 7 days) and has been shown to be inferior to pegfilgrastim at reducing FN incidence, hospitalisations and 
maintaining RDI. Once-per-cycle administration with pegfilgrastim might also aid patient adherence. The introduction of 
biosimilar pegfilgrastim should instigate a rethink of neutropenia management. Biosimilar pegfilgrastim offers countries 
using biosimilar filgrastim opportunities to improve adherence and thus cancer survival, whilst offering economic benefits 
for countries using reference pegfilgrastim. These benefits can be realised in full if biosimilar pegfilgrastim becomes part 
of routine clinical practice supported by drug and therapeutic committees implementing guidelines with multidisciplinary 
support in the hospital.
1 Introduction
Febrile neutropenia (FN) is one of the most serious compli-
cations of cancer chemotherapy and can lead to fatal con-
sequences, such as sepsis [1]. FN further reduces cancer 
patient survival rates through delays, dose reductions and 
discontinuations of chemotherapy schedules [2, 3]. As well 
as being a medical emergency with significant clinical bur-
den, the economic burden of FN, particularly related to 
hospitalisations, is substantial [4, 5]. Granulocyte colony-
stimulating factors (G-CSFs) have been proven effective 
in reducing the incidence of FN and are recommended for 
the prevention of chemotherapy-induced neutropenia in 
international guidelines [1, 5]. There are two main types 
of G-CSF: filgrastim, which is administered daily during 
the chemotherapy cycle, and pegfilgrastim, a pegylated 
form of filgrastim, which allows administration once per 
cycle [4]. Biosimilars of filgrastim have been available in 
Europe since 2008 [6]. Biosimilars are lower-cost versions 
of already authorised reference medicines with comparable 
physicochemical and biological characterisation and clini-
cal effectiveness and safety [7]. The cost reductions induced 
by the introduction of biosimilar filgrastim has resulted in 
increased access to this therapy, with Sweden, for example, 
documenting a 5-fold increase in reimbursed usage [6]. In 
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New Zealand, expanded use of G-CSF as primary rather than 
secondary prophylaxis following the introduction of biosimi-
lar filgrastim has seen the number of breast cancer patients 
hospitalised due to chemotherapy-induced FN decline from 
one third of women to < 7% [8]. The first pegfilgrastim bio-
similars were approved in Europe in September 2018 and in 
the US in November that year; there are currently seven such 
products approved in Europe and three in the US (Table 1). 
This review aims to explore whether biosimilar pegfilgrastim 
will have a similar impact to that of biosimilar filgrastim and 
further improve clinical outcomes and cost effectiveness in 
patients undergoing cytotoxic chemotherapy.
2  Methods
This narrative review was developed by oncologists (MA, 
PC and PG) and a pharmacist (AV) who are experts in 
G-CSF and biosimilars and have published widely on the 
subject matter. Two of the authors (PC and PG) have recently 
published a systematic review and meta-analysis of all trials 
of G-CSF or pegfilgrastim for both randomised and non-
randomised comparisons using Cochrane methodology [4]. 
A further non-systematic review of the relevant literature in 
PubMed and the Cochrane Library was undertaken, which 
was supplemented by studies identified by the authors. The 
importance of G-CSF as primary prophylaxis for chemother-
apy-induced neutropenia and the role of pegfilgrastim was 
summarised and recommendations on the implementation 
of biosimilar pegfilgrastim provided, predicated on the best 
available evidence and the authors’ experiences with (bio-
similar) G-CSF and biosimilars in general.
3  Burden of Febrile Neutropenia
FN is one of the most feared complications of chemotherapy 
and is classed as a medical emergency [5].
FN is defined by the European Society of Medical Oncol-
ogy (ESMO) as “an oral temperature of > 38.3 °C or two 
Table 1  Biosimilars of pegfilgrastim approved in Europe and the US
a As reported in EMA EPAR available at https ://www.ema.europ a.eu
b EMA Grasustek EPAR. Available at https ://www.ema.europ a.eu/en/medic ines/human /EPAR/grasu stek
EMA European Medicines Agency, EPAR European public assessment report, FDA The Food and Drug Administration
Brand name Manufacturer Registration trial EMA approval FDA approval
Pelgraz® Accord Healthcare Desai et al. 2018 [56]
 Phase III randomised, assessor-blinded, multicentre study 
on 589 breast cancer patients with reference arms of  
US–Neulasta and EU–Neulasta
September 2018
Udenyca® Coherus Dose–response  triala September 2018 November 2018
Fulphila® Mylan Waller et al. 2019 [57]
 Phase III randomised, assessor-blinded study on 194 
breast cancer patients with reference arm of  
EU–Neulasta
November 2018 June 2018
Pelmeg® Cinfa Biotech/Mundipharma Dose-response  triala November 2018
Ziextenzo® Sandoz Harbeck et al. 2016 [58]
 Phase III randomised, assessor-blinded, multicentre study 
on 316 breast cancer patients with reference arm of  
EU–Neulasta
November 2018 November 2019
Grasustek® Juta Pharma Grasustek (EPAR)b
 Phase III randomised, assessor-blinded, multicentre study 
on 254 breast cancer patients with reference arm of  
EU–Neulasta
April 2019
Pegfilgrastim 
 Mundipharma®
Mundipharma Dose-response  triala December 2019
Key Points 
Pegfilgrastim has been shown to be superior to filgrastim 
at reducing chemotherapy-related neutropenia and at 
achieving target dose intensity, as the latter is often 
under-dosed in clinical practice.
Use of biosimilar pegfilgrastim will facilitate access and, 
supported by guidelines and clinical rules, enable the full 
potential of these life-saving benefits to be realised at 
reduced cost.
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consecutive readings of > 38.0 °C for 2 h and an absolute 
neutrophil count (ANC) of < 0.5 × 109/L, or expected to fall 
below 0.5 × 109/L” [5]. It has been estimated that the inci-
dence of FN might be as high as 117 cases per 1000 cancer 
patients [9]. FN causes a significant medical burden, with up 
to 30% of cases requiring inpatient hospital care and mortal-
ity rates in the range of 2–21% [5, 10]. In 2012, the Office 
of National Statistics reported approximately two deaths 
per day in England and Wales from neutropenic sepsis [11]. 
Patients spend an average of 9–10 days in hospital per neu-
tropenic episode [12, 13]. The economic consequences of 
FN are substantial, with ESMO estimating in 2016 that the 
mean cost of an FN hospitalisation in Western countries was 
approximately €13,500 [5].
4  Benefits of Granulocyte 
Colony‑Stimulating Factor (G‑CSF) 
Prophylaxis
G-CSFs are biological growth factors that stimulate the 
production, differentiation and activation of neutrophils in 
the bone marrow, thereby reducing the risk, severity and 
duration of neutropenia [2, 10]. A key factor when consider-
ing G-CSF is the ANC nadir (the lowest value to which the 
neutrophil count will fall following drug administration); if 
the nadir depth and duration can be limited, there are less 
likely to be complications or chemotherapy dose reductions 
and delays from neutropenia [14, 15]. To minimise the ANC 
nadir, filgrastim is administered as a daily dose of 5 µg/kg 
at least 24 hours after each chemotherapy administration 
and within 3–4 days after cycle completion. Pegfilgrastim 
is given as one 6-mg dose per cycle and should be adminis-
tered the day after initiating chemotherapy; however, admin-
istration up to 3–4 days after initiation may also be reason-
able [5, 16–18].
Prophylactic use of G-CSF reduces the incidence of FN 
and infection-related mortality whilst, importantly, main-
taining the relative dose intensity (RDI) of chemotherapy 
and, thereby, improving cancer outcomes [19, 20]. RDI has a 
major influence on the efficacy and survival rates of patients 
receiving chemotherapy for chemo-sensitive tumours. A 
clear dose–response effect of adjuvant chemotherapy was 
first demonstrated by Bonadonna and Valagussa in 1981 
[21] and confirmed at the 20-year follow-up [22]. In the UK 
SPROG trial (A Randomised Trial of Secondary Prophy-
laxis using Granulocyte Colony Stimulating Factor), it was 
reported that 75% of patients with breast cancer received 
their target of 85% planned RDI of adjuvant chemotherapy 
with 7 days of filgrastim or pegfilgrastim, compared with 
only 50% of those not receiving G-CSF (p < 0.0001) [23]. 
Findings from a meta-analysis provide the most compelling 
evidence of the importance of G-CSF to cancer outcomes. 
In this analysis of data from 61 randomised controlled tri-
als (RCTs) involving 11,337 patients who received G-CSF 
and 13,456 controls, G-CSF was found to increase absolute 
cancer survival rates by 3.2% [24]. To put this into context, 
this compares with a 2–3% absolute survival benefit for 
adjuvant chemotherapy given to early-stage, node-negative 
breast cancer patients aged 50–69 years [25]. The impor-
tance of the impact of G-CSF on long-term cancer outcomes 
is recognised by its status as a World Health Organization 
(WHO) Essential Drug, meaning that it should be provided 
with sufficient reimbursement to be accessed for free, or at 
prices affordable to all [26].
5  G‑CSF Guidelines
Established guidelines regarding G-CSF use in the pre-
vention of chemotherapy-induced FN have been issued by 
ESMO, the European Organisation for Research and Treat-
ment of Cancer (EORTC), the National Comprehensive 
Cancer Network (NCCN) and the American Society of 
Clinical Oncology (ASCO) [1, 5, 16, 17]. G-CSF is recom-
mended as primary prophylaxis of chemotherapy-induced 
neutropenia when the overall risk of FN for the prescribed 
regimen is ≥ 20% (Fig. 1). For patients prescribed chemo-
therapy with a 10–20% risk of FN, G-CSF use should be 
considered in those with additional risk factors placing them 
at enhanced risk, such as age > 65 years, coexisting morbid-
ities or prior history of FN. Patients on low-risk regimens 
(< 10% risk of FN) are not recommended G-CSF prophy-
laxis. If primary prophylaxis was not prescribed, G-CSF is 
recommended as secondary prophylaxis for patients who 
have had a neutropenic complication from a previous cycle 
of chemotherapy [1, 5, 16, 17]. However, it should be noted 
that the majority of neutropenic complications occur in the 
earliest cycles of chemotherapy; for example, across two tri-
als involving high-risk breast cancer patients, the incidence 
of grade 4 neutropenia in cycle 1 was approximately 80%, 
but fell to 50% by cycle 4 [14, 27]. Such data emphasises 
the importance of primary as opposed to secondary G-CSF 
prophylaxis [28].
Primary prophylaxis with G-CSF should start with the 
first cycle of chemotherapy and continue throughout subse-
quent cycles [1, 5, 16, 17]. ESMO recommends administra-
tion of filgrastim for around 10 days [5], whilst a recently 
published expert consensus recommends that pegfilgrastim 
should always be administered in preference to a duration 
of daily filgrastim of < 11 days [9]. Pegfilgrastim use is sup-
ported in different length chemotherapy cycles, including 
fortnightly, albeit data are more limited in patients receiving 
weekly regimens, where filgrastim might be preferred [9]. 
For patients on chemotherapy at a high risk of FN (≥ 20%) 
or intermediate risk of FN (10–20%) plus additional risk 
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factors, pegfilgrastim is generally considered the G-CSF of 
choice to maintain RDI and avoid the severe complications 
associated with FN, due to the simplified administration 
compared with filgrastim supporting higher adherence and, 
therefore, coverage of the ANC nadir [9, 29].
The availability of biosimilar pegfilgrastim offers a fresh 
opportunity to ensure the proper application of these guide-
lines. A multidisciplinary approach is required both for the 
implementation of evidenced-based guidelines as well as the 
adoption of biosimilars into day-to-day practice, and these 
processes can be linked to mutual benefit. Four key princi-
ples can help guide the implementation of biosimilars within 
a region or country:
1. Multi-stakeholder approach: involve everybody from top 
to bottom in your healthcare setting and educate about 
biosimilars.
2. One-voice principle: the whole team should talk about 
biosimilars in a positive way and avoid sending confused 
or mixed messages (this will greatly reduce any nocebo 
effect).
3. Shared decision making: inform the patient about the 
fact that treatment is initiated/continued with a biosimi-
lar, an equally effective and safe alternative.
4. Gain sharing: introduction of biosimilars requires extra 
effort (= time) from busy healthcare professionals. A 
part of the savings from biosimilars should benefit the 
clinical department that generate the savings.
This process, for example, could be led by a pharmacist, 
involving presentations and discussions with the oncology 
physicians and nursing staff. Computer order systems for 
anticancer therapies could be leveraged to link biosimilar 
pegfilgrastim to chemotherapy regimens with a high risk of 
FN. In this way, implementation of the G-CSF guidelines 
can be assured as well as the adoption of biosimilar pegfil-
grastim into routine practice. It cannot be overstressed the 
importance that all healthcare professionals involved in the 
care of cancer patients are in agreement about when to use 
G-CSF support and the use of biosimilar pegfilgrastim to 
ensure an efficient and long-term solution. The use of clini-
cal rules, whereby pharmacists work collaboratively with 
physicians to ensure guidelines are implemented, will sup-
port and facilitate this.
6  Pegfilgrastim Versus Filgrastim
Numerous studies have compared the efficacy and safety of 
pegfilgrastim and filgrastim [4, 15, 30–32]. A recent meta-
analysis identified 36 studies that reported a direct, head-
to-head comparison of pegfilgrastim versus filgrastim [4]. 
In 12 RCTs, the relative risk (RR) of developing FN was 
lower for pegfilgrastim compared with filgrastim, but the 
difference was not statistically significant (0.86; p = 0.226). 
Importantly, however, in 24 non-RCTs, the overall risk 
was significantly lower with pegfilgrastim than filgrastim 
for the incidence of FN (RR 0.67; p = 0.023), FN-related 
Fig. 1  Algorithm for assess-
ing FN risk and the need for 
primary prophylactic G-CSF. 
Adapted from guidelines by 
the European Organisation for 
Research and Treatment of Can-
cer [1], the European Society of 
Medical Oncology [5] and the 
National Comprehensive Cancer 
Network [16]. FN febrile neu-
tropenia, G-CSF granulocyte-
colony stimulating factor
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hospitalisations (RR 0.68; p < 0.05) and chemotherapy dose 
delays (RR 0.68; p = 0.020). It was postulated by the authors 
that the greater efficacy of pegfilgrastim in non-RCTs might 
reflect under-dosing of filgrastim in routine clinical prac-
tice, as reflected in 11 of 12 RCTs that administered seven 
or more doses of short-acting G-CSF versus only 2 of 24 
non-RCTs [4]. When dosed equivalently (one dose of peg-
filgrastim and 10–14 days of filgrastim), the safety profiles 
(e.g. bone pain) have been shown to be similar [31].
Several studies have reported that under-dosing of fil-
grastim is prevalent in routine clinical practice [33–37]. 
Under-dosing of filgrastim has been reported in 17.4% of 
patients in Europe [37], with the median schedule used being 
only 5 days [38]. Under-dosing by weight is also common 
practice, with a German study reporting that approximately 
three-quarters of patients received the 300-µg (30-MU) dose 
of filgrastim (recommended for body weight up to 60 kg), 
when the average body weight (in Germany) is 75.6 kg [35].
There are a number of possible reasons for the wide-
spread under-dosing of filgrastim. A key reason is likely 
to be that filgrastim has always been available in a pack 
of five and from the earliest days of its use, patients were 
often prescribed one pack of 300 µg for reasons of cost and 
convenience. Although the advent of biosimilar filgrastim 
has removed or at least significantly diminished the cost ele-
ment, it appears to still be habitual practice to prescribe a 
single pack of five [35]. A survey of healthcare professionals 
(HCPs) from six European countries (Germany, Italy, Portu-
gal, Poland, Lithuania and Latvia) undertaken in early 2019 
to support this review found that almost half (48%; 42/88) 
of HCPs (89% physicians; 11% pharmacists) did not fol-
low weight-based dosing of filgrastim and nearly two-thirds 
(64%; 56/88) prescribed a course of < 7 days (Fig. 2). The 
reason is fundamentally simple: physician and pharmacist 
co-responsibility for proper use has not been implemented 
in the majority of hospitals. Patient adherence with the fil-
grastim regimen is another potentially salient reason for 
under-dosing. Lack of physician familiarity or awareness 
of the G-CSF guidelines and/or the consequences of FN on 
RDI and, thereby, cancer survival is likely to be another 
factor behind under-dosing of filgrastim and under use of 
G-CSF in general [39–41]. In Germany, for example, despite 
85.1% of 195 physicians stating that they followed G-CSF 
guidelines, evidence revealed only 15.4% adherence for 
high-risk lung cancer patients and < 50% for intermediate-
risk lung and breast cancer patients [41]. Lack of risk fac-
tors was cited by over half the physicians as a reason for not 
using G-CSF in patients prescribed a chemotherapy with 
a FN risk ≥ 20% [41], yet the assessment of risk factors in 
this group of patients is unnecessary and only required for 
intermediate- or low-risk groups [1, 5, 16]. Overall, it has 
been reported that as many as 80% of patients do not receive 
primary prophylaxis with G-CSF in accordance with their 
assessed risk [39, 41]. Dose reductions of chemotherapy 
related to neutropenia and use of G-CSF only as secondary 
prophylaxis have also been found to be widespread in clini-
cal practice [39, 41].
Fig. 2  European survey results 
highlighting the under-dosing 
of filgrastim by both weight and 
duration of therapy. The survey 
of 88 healthcare professionals 
(78 physicians; 10 pharmacists) 
from six European countries 
(Germany n = 3; Italy n = 7; 
Portugal n = 31; Poland n = 29; 
Lithuania n = 12; Latvia n = 6) 
was undertaken in April–May 
2019. Respondents were based 
in oncology clinics (n = 3); 
general hospitals (n = 36); or 
specialist haematology or oncol-
ogy centres (n = 48). HCPs 
healthcare professionals
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This widespread reporting of under-dosing (by weight-
adapted dose and duration of therapy), with lack of adher-
ence to both prescribing guidelines and the approved drug 
label for G-CSF, is striking. Given the proven impact of 
filgrastim on cancer cure, it is hard to imagine that such a 
situation would be considered appropriate for other aspects 
of curative cancer treatment, such as radiation or chemo-
therapy doses and schedules [24].
Awareness and adherence to G-CSF guidelines can be 
improved through educational workshops, training courses 
and lectures, as demonstrated in Germany, where such inter-
ventions increased G-CSF use in alignment with guidelines 
from 15.4 to 47.8% in high-risk FN lung cancer patients 
undergoing chemotherapy [42]. Whilst initiatives such as 
this represent a good start, more still needs to be done as 
adherence rates of < 50% remain unacceptable, since this 
can jeopardise patient survival by increasing the risk of hos-
pitalisations with neutropenic complications and the likeli-
hood of interruptions to or discontinuation of chemotherapy 
treatment. The goal is to change practice in the long term 
and this requires a multidisciplinary approach with multiple 
forms of interventions. One of the most successful strategies 
to improve clinical practice and quality of care are clinical 
rules, whereby pharmacists support physicians by ensuring 
complete execution of a clinical protocol, such as the addi-
tion of laxatives when prescribing opioids. A concerted, 
pan-European programme, driven by a key society such as 
ESMO together with the European Association of Hospital 
Pharmacists (EAHP) and supported by individual country 
initiatives or national associations, is recommended to max-
imise the potential of G-CSF therapy to improve cancer cure 
rates and survival.
Pegfilgrastim offers distinct advantages over filgrastim 
in supporting adherence to G-CSF guidelines and in help-
ing to ensure patients obtain sufficient G-CSF coverage dur-
ing their chemotherapy. As a single 6-mg dose per cycle, 
pegfilgrastim obviates any weight-based dosing errors and 
insufficient duration of use that can occur with filgrastim [4, 
5]. In addition, the once-per-cycle administration of pegfil-
grastim may increase patient adherence, as the need for daily 
administration, daily hospital visits and regular testing of 
ANC levels is eliminated [9]. Fewer hospital visits might 
also improve patient quality of life, particularly for older 
or frail patients, and reduce the risk of nosocomial infec-
tions, as well as saving the associated hospital resource use. 
Adherence to G-CSF guidelines has been shown to be higher 
with pegfilgrastim than filgrastim. In an Italian observational 
study of 645 consecutive patients and 3150 chemotherapy 
administrations, it was revealed that physicians were more 
likely to follow guidelines with pegfilgrastim compared with 
short-acting G-CSF (66% vs 47%, respectively; p = 0.002) 
[43]. Furthermore, pegfilgrastim was administered at 
the correct time in 93.2% of patients compared with only 
61.5% of patients receiving short-acting G-CSF (p < 0.0001) 
[43]. There is also some evidence that pegfilgrastim might 
improve RDI of chemotherapy compared with filgrastim. 
In the SPROG trial, 84.9% of breast cancer patients who 
received pegfilgrastim as secondary prophylaxis achieved 
85% planned RDI of adjuvant chemotherapy compared 
with 69.5% of patients on 7 days of filgrastim (no p value 
reported) [23].
7  Assessing the Value of Biosimilar 
Pegfilgrastim
As cancer incidence continues to rise and the costs of novel 
therapies ever increase, the need to find cheaper but equally 
effective therapies is paramount for the sustainability of 
healthcare systems. Biosimilars are as clinically effective as 
reference products and can be > 30% cheaper, with cumula-
tive savings across the five major European Union (EU) mar-
kets and the US estimated to reach €50–100 billion between 
2016 and 2020 [44]; creating headroom in healthcare budg-
ets for new medicines. Since 2006, 58 biosimilars have been 
approved in Europe, including six biosimilars of filgrastim 
[45]. As a result of the introduction of biosimilars, access to 
biologics has increased by as much as 100% in the EU [44]. 
Initial concerns surrounding the efficacy and safety of bio-
similars and the risks surrounding extrapolation of data and 
immunogenicity have proven to be completely unfounded 
[6, 46, 47]. In a decade of use, biosimilar filgrastim has 
proven to be equally as effective and well tolerated as ref-
erence filgrastim, whilst providing cost savings (conserva-
tively estimated to be 39% in Europe), increased access and 
a resultant decrease in FN-related hospitalisations [6, 8, 
48, 49]. The recent licensing in Europe of seven biosimilar 
pegfilgrastim-containing products (as of December 2019) 
offers the opportunity to deliver the additional advantages of 
long- over short-acting G-CSF at a reduced cost. Biosimilar 
pegfilgrastim costs approximately €650 and filgrastim €100 
per dose (based on list prices in the UK and France) [50, 
51], meaning that at least six or seven doses of biosimilar 
filgrastim need to be prescribed to achieve price parity (with 
the caveat that any local or regional discounts etc. may affect 
this ratio). Hence, different approaches to adoption of bio-
similar pegfilgrastim may be required depending on whether 
a country/jurisdiction is using predominantly reference peg-
filgrastim or biosimilar filgrastim.
For countries using predominantly filgrastim biosimilars, 
the advantages of biosimilar pegfilgrastim are manifest in 
the simplified once-per-cycle dosing; improving adherence 
and appropriate coverage of the ANC nadir, and, thereby, 
fewer neutropenic events and FN-related deaths, increased 
RDI and improved cancer survival. All countries currently 
using filgrastim are urged to audit current usage to determine 
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if under-dosing is commonplace, by number of doses and/
or weight, and the implications of this on planned chemo-
therapy schedules and RDI (See Online Resource 1 in the 
electronic supplementary material for a suggested minimum 
dataset). Data from such audits should be taken into account 
when considering the relative costs versus benefits of bio-
similar pegfilgrastim and biosimilar filgrastim. If a country 
is using the appropriate dosage of filgrastim (10–14 days), 
it may be that direct cost savings can be achieved with the 
introduction of biosimilar pegfilgrastim (e.g. €1000–€1400 
vs €650 per cycle, respectively, using the prices quoted 
above).
For countries currently using reference pegfilgrastim, 
there are evident cost savings to be made of > 30% or more 
by switching to biosimilar pegfilgrastim, which could sup-
port increased access to this important therapy and/or free 
up additional funds in the cancer drugs budget [44]. The 
introduction of biosimilar pegfilgrastim will also increase 
competition in those countries using predominantly lipeg-
filgrastim, a second-in-class long-acting G-CSF.
In terms of choice of biosimilar pegfilgrastim, competi-
tion between manufacturers will likely result in the products 
being priced similarly, as is seen with biosimilars in other 
therapeutic areas. Assuming price parity, the choice of bio-
similar may come down to a choice of device, as this can 
have a potentially strong influence on adherence. It is well 
known across all areas of medicine that patient anxiety and 
fear of needles can lead to poor adherence [52–54]. The 
biosimilar pegfilgrastim considered to have the most easy-to-
use device, for example, with a shorter and smaller diameter 
or hidden needles, would likely lead to improved adherence 
[54]. Processes to ensure that the rubber plunger does not 
stiffen with age and increase friction and, thereby, cause 
problems with delivery of the full dose are also a key consid-
eration [55]. A simple, patient-friendly device would likely 
increase patients’ willingness to self-administer at home, 
as well as increase the efficiency of nurse delivery; which 
could provide further cost savings. Improving adherence to 
G-CSF therapy, and thereby optimising chemotherapy treat-
ment and improving outcomes, could result in substantial 
savings in the cost of disease management and should be 
considered when deciding upon which pegfilgrastim bio-
similar to prescribe.
8  Conclusions
Primary prophylaxis with G-CSF for patients on high-risk 
(≥ 20%) chemotherapies, or those on intermediate-risk 
(10–20%) chemotherapies plus additional risk factors, is 
critical to improving cancer patient survival by ensuring 
dose intensity of cancer therapy is maintained. It would be 
unacceptable for patients not to receive their full course of 
adjuvant radiotherapy, and the same standard should apply 
for chemotherapy. In clinical practice, the use of pegfil-
grastim has been shown to be clinically superior to filgrastim 
at reducing neutropenic events and FN [4], improving adher-
ence to G-CSF guidelines [43] and at achieving target RDI 
[23], as the latter is frequently under-dosed [4, 36, 37]. Bio-
similar pegfilgrastim offers a fresh opportunity to rethink 
neutropenia management and the value of G-CSF in 2020, 
based on the significant potential for both clinical and eco-
nomic benefits (Table 2). A concerted, multidisciplinary 
action, involving prescribing physicians, oncology nurses 
and pharmacists, supported by guidelines and clinical rules, 
will release the full potential of this life-saving strategy.
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Table 2  Key clinical and economic benefits offered by biosimilar pegfilgrastim
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